Antisense oligonucleotides against TNFR1 prevent toxicity of TNF/IFNγ treatment in mouse tumor models

International Journal of Cancer

Volumn 135, Issue 3, 2014, Pages 742-750

  Van Hauwermeiren, Filip ^a   Vandenbroucke, Roosmarijn E ^a   Grine, Lynda ^a   Puimège, Leen ^a   Van Wonterghem, Elien ^a   Zhang, Hong ^b,c   Libert, Claude ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligonucleotides; TNF IFN therapy; TNFR1; Toxicity

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HYPOTHERMIA; LETHALITY; LEWIS CARCINOMA; LUNG CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE LEVEL;

ANTISENSE OLIGONUCLEOTIDES; TNF/IFNΓ THERAPY; TNFR1; TOXICITY;

ANIMALS; CARCINOMA, LEWIS LUNG; DISEASE MODELS, ANIMAL; FEMALE; INTERFERON-GAMMA; INTESTINE, SMALL; LIVER; MAXIMUM TOLERATED DOSE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901014207     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28704     Document Type: Article

References (39)

1. Kollias G, Douni E, Kassiotis G, et al. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, #rheumatoid |arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 1999; 58 (Suppl 1): I32-I39.
2. Brouckaert PG, Leroux-Roels GG, Guisez Y, et al. In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. Int J Cancer 1986; 38: 763-9.
3. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-4.
4. Lejeune FJ, Ruegg C, Lienard D,. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 1998; 10: 573-80.
5. Grunhagen DJ, de Wilt JH, Graveland WJ, et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006; 106: 1776-84.
6. Ruegg C, Yilmaz A, Bieler G, et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998; 4: 408-14.
7. Karin M, Greten FR,. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-59.
8. Van Hauwermeiren F, Armaka M, Karagianni N, et al. Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium. J Clin Invest 2013; 123: 2590-603.
9. Senzer N, Mani S, Rosemurgy A, et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 2004; 22: 592-601.
10. Thamm DH, Kurzman ID, Clark MA, et al. Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation. Clin Cancer Res 2010; 16: 1498-508.
11. Brouckaert P, Ameloot P, Cauwels A, et al. Receptor-selective mutants of tumour necrosis factor in the therapy of cancer: preclinical studies. Circ Shock 1994; 43: 185-90.
12. Gerspach J, Pfizenmaier K, Wajant H,. Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects. Biofactors 2009; 35: 364-72.
13. Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000; 18: 1185-90.
14. Wielockx B, Lannoy K, Shapiro SD, et al. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med 2001; 7: 1202-8.
15. Takahashi N, Vanlaere I, de Rycke R, et al. IL-17 produced by Paneth cells drives TNF-induced shock. J Exp Med 2008; 205: 1755-61.
16. Duprez L, Takahashi N, Van Hauwermeiren F, et al. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity 2011; 35: 908-18.
17. Huys L, Van Hauwermeiren F, Dejager L, et al. Type I interferon drives tumor necrosis factor-induced lethal shock. J Exp Med 2009; 206: 1873-82.
18. Vandenabeele P, Declercq W, Beyaert R, et al. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 1995; 5: 392-9.
19. Rothe J, Lesslauer W, Lotscher H, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993; 364: 798-802.
20. Stoelcker B, Ruhland B, Hehlgans T, et al. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol 2000; 156: 1171-6.
21. Cummins LL, Owens SR, Risen LM, et al. Characterization of fully 2'-modified oligoribonucleotide hetero-and homoduplex hybridization and nuclease sensitivity. Nucleic Acids Res 1995; 23: 2019-24.
22. Bennett CF, Swayze EE,. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259-93.
23. van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007; 357: 2677-86.
24. Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 2013; 12: 435-42.
25. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 998-1006.
26. Gleave ME, Monia BP,. Antisense therapy for cancer. Nat Rev Cancer 2005; 5: 468-79.
27. Granger DL, Hibbs JB, Jr, Broadnax LM,. Urinary nitrate excretion in relation to murine macrophage activation. Influence of dietary L-arginine and oral NG-monomethyl-L-arginine. J Immunol 1991; 146: 1294-302.
28. Van Snick J, Cayphas S, Vink A, et al. Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci USA 1986; 83: 9679-83.
29. Huang XW, Yang J, Dragovic AF, et al. Antisense oligonucleotide inhibition of tumor necrosis factor receptor 1 protects the liver from radiation-induced apoptosis. Clin Cancer Res 2006; 12: 2849-55.
30. Cauwels A, Van Molle W, Janssen B, et al. Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase. Immunity 2000; 13: 223-31.
31. Smith JW, II, Urba WJ, Clark JW, et al. Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma. J Immunother 1991; 10: 355-62.
32. Teplova M, Minasov G, Tereshko V, et al. Crystal structure and improved antisense properties of 2'-O-(2-methoxyethyl)-RNA. Nat Struct Biol 1999; 6: 535-9.
33. Walder RY, Walder JA,. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA 1988; 85: 5011-15.
34. Geary RS, Watanabe TA, Truong L, et al. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 2001; 296: 890-7.
35. Agrawal S, Temsamani J,. Comparative pharmacokinetics of antisense oligonucleotides. Methods Mol Med 1996; 1: 247-70.
36. Whitehead KA, Langer R, Anderson DG,. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009; 8: 129-38.
37. Myers KJ, Murthy S, Flanigan A, et al. Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis. J Pharmacol Exp Ther 2003; 304: 411-24.
38. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
39. Van Hauwermeiren F, Vandenbroucke RE, Libert C,. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev 2011; 22: 311-19.